1. Dalhoff, A., Petersen, U.& Endermann, R. (1996). In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy42, 410–25.
2. A Guide to Sensitivity Testing. (1991). Journal of Antimicrobial Chemotherapy27, Suppl. D,1–50.
3. Wise, R., Andrews, J. M.& Hartman, G. (1998). The pharmacokinetics and penetration of moxifloxacin into a cantharidine induced inflammatory exudate following oral and intravenous administration. In Program and Abstracts of the Thirty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract A27, p. 8. American Society for Microbiology, Washington, DC.
4. Grimm, H. (1999). Moxifloxacin: tentative interpretative criteria for the disc susceptibility testing using the German DIN 58940 method. In Abstracts of the Ninth European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, 1999. Abstract P220, p. 143. Clinical Microbiology and Infection5, Suppl. 3.
5. Krasemann, C., Meyer, J. M.& Springsklee, M. (1999). Suggested breakpoints for moxifloxacin. In Abstracts of the Ninth European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, 1999. Abstract P206, p. 139. Clinical Microbiology and Infection5, Suppl. 3.